Manhattan Scientifics Inc. Stock Chart Mimics That of Its Largest Investment to Date: Imagion Biosystems

Rhea-AI Summary

Manhattan Scientifics Inc. (OTCQB: MHTX) has invested $30 million and committed to a 10-year effort to commercialize a non-invasive cancer diagnostic in partnership with MD Anderson Cancer Center. The company is currently awaiting regulatory approval to commence human trials. The CEO expressed intentions to enhance shareholder value, despite the company's market cap fluctuations, which have seen a peak near $1 billion and a low of $17 million.

Positive

• Investment of $30 million in cancer diagnostic technology.
• Partnership with MD Anderson Cancer Center for enhanced credibility.
• Potential for early cancer detection could revolutionize treatment outcomes.

Negative

• Current market cap significantly lower than its historical peak, indicating volatility.
• Awaits regulatory approval, introducing uncertainty and potential delays.

Manhattan Scientifics Inc. (OTCQB: MHTX) invested $30 million and a 10-year effort to commercialize the Imagion Biosystems (IBX: AX) super early, non- invasive, non-radioactive Cancer diagnostic, now “partnered” with MD Anderson Cancer Center, Houston. The company is awaiting regulatory approval to initiate human cancer trials.

View the stock chart.

“Very early detection of cancer may ultimately lead to the end of the dreaded disease,” stated a senior cancer physician.

Manhattan Scientifics’ founder, Marvin Maslow and CEO Manny Tsoupanarias pioneered the developments of HDTV, hydrogen fuel cells, Haptics, and other cutting edge space-age technologies.

Maslow stated, “We did it before and we’ll do it again and it won’t be difficult.” Manny T. continued, “As early investors in disruptive technologies, we’ve seen our market cap rise to approach $1.0 billion and fall to $17M we intend to create increased shareholder values going forward.”

About Manhattan Scientifics, Inc.

Manhattan Scientifics Inc. (www.mhtx.com) is focused on technology transfer and commercialization of transformative technologies.

Forward-looking statement

This press release contains forward-looking statements, which are subject to a number of risks, assumptions and uncertainties that could cause the Company's actual results to differ materially from those projected in such forward-looking statements. Management at Manhattan Scientifics believes that purchase of its shares should be considered to be at the high end of the risk spectrum. Forward-looking statements speak only as of the date made and are not guarantees of future performance. We undertake no obligation to publicly update or revise any forward-looking statements.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210311005814/en/

FAQ

What is the latest investment by Manhattan Scientifics Inc. related to cancer diagnosis?

Manhattan Scientifics Inc. invested $30 million in a non-invasive cancer diagnostic in partnership with MD Anderson Cancer Center.

What is the stock symbol for Manhattan Scientifics?

The stock symbol for Manhattan Scientifics is MHTX.

What are the potential risks mentioned in the press release for MHTX?

The press release notes that investment in MHTX shares is considered to be at the high end of the risk spectrum due to uncertainties in regulatory approvals.

When will Manhattan Scientifics begin human trials for their cancer diagnostic?

Manhattan Scientifics is currently awaiting regulatory approval to initiate human cancer trials.

What has caused the fluctuation in Manhattan Scientifics' market cap?

The market cap of Manhattan Scientifics has fluctuated due to various factors, including investment successes and challenges in commercializing technology.